Your session is about to expire
← Back to Search
Cabozantinib + Fulvestrant for Metastatic Hormone-Receptor-Positive Breast Cancer
Study Summary
This trialtests a drug that blocks proteins involved in breast cancer growth, spread, and blood vessel formation. It may help stop cancer growth.
- Breast Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are expected to live for at least 3 more months.You are currently taking blood thinners or medications that prevent blood clotting.Your organs and bone marrow are working properly.You have received an organ transplant in the past.You have already tried more than one type of chemotherapy for metastatic breast cancer treatment.You have received treatment with fulvestrant in the past.You have a severe wound, ulcer, or bone fracture that is not healing properly.You have had an allergic reaction or are hypersensitive to any of the ingredients in the study treatment.You have already received at least one round of hormone therapy or chemotherapy for your advanced disease.You have brain metastasis (cancer spread to the brain) that is causing symptoms and needs treatment, including medication to reduce swelling and prevent seizures.You have severe digestive system problems that could lead to holes or abnormal connections in your organs.
- Group 1: Cabozantinib plus fulvestrant
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have any other research initiatives explored the effects of combining Cabozantinib and fulvestrant?
"In 2004, Lowell General Hospital began researching the combination of cabozantinib plus fulvestrant. Since then, 145 studies have been concluded and 241 are now recruiting participants — with a large portion being Boston-based."
To what degree is the combination of Cabozantinib and fulvestrant a hazard for individuals?
"The existing data on cabozantinib plus fulvestrant suggests that it is safe, and thus our team at Power have given this medication a score of 2. As it is only in Phase 2 trials, there has been no evidence to support its efficacy yet."
In what clinical scenarios is Cabozantinib plus fulvestrant often prescribed?
"Cabozantinib plus fulvestrant is primarily used for individuals that have already had anti-vegf treatment. Other indications include renal cell carcinoma, high risk patients and those receiving sorafenib therapy."
How many participants have consented to participate in the trial thus far?
"This research initiative is no longer accepting patients. Its initial posting was on October 1st 2011, and the most recent updates were made on December 21st 2022. If you are still looking for studies to join, there are 2624 trials related to breast cancer that have open enrollment slots, and 241 clinical programs involving cabozantinib plus fulvestrant currently recruiting participants."
Are there opportunities for people to join this experimental research?
"At this juncture, recruitment for this clinical trial has been suspended. This study was first posted on October 1st 2011 and last edited on December 21st 2022. If you are searching for other studies related to breast cancer, there exists 2,624 trials actively recruiting; alternatively, 241 separate medical trials involving Cabozantinib plus fulvestrant are presently seeking participants."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger